The increasing interest in the Special Purpose Acquisition Company (SPAC) in Life Sciences, accelerated perhaps by the disruption and market dynamics created by Covid-19, is evident. The attraction of SPACs in principle to investors and Life Science companies is on the surface very clear. More stable, reduced risk, less burdensome and potentially more rapid route to an IPO. There may also be benefits in terms of valuation and pricing certainty. The importance on its ESG factors could be critical to success so this session will discuss the key considerations when creating and operating a SPAC such as the pros and cons, legal framework, leadership and governance, investment bank and market engagement and the IPO.
The event is free to attend and open to all.